

ALASKA MEDICAID
Prior Authorization Criteria

**Calcitonin gene-related peptide
receptor antagonists (i.e.
erenumab, fremaexumab, etc.)**

FDA INDICATIONS AND USAGE^{1,2,4}

Calcitonin gene-related peptide receptor antagonists are indicated for the preventive treatment of migraine in adults.

APPROVAL CRITERIA^{1,2,3}

1. Patient is within the age range recommended by the FDA label **AND;**
2. Prescribed in consultation with or is a headache specialist, pain specialist, or neurologist **AND;**
3. Patient has the diagnosis of episodic or chronic migraine **AND;**
4. Patient is experiencing 4 or more documented migraine days per month **AND;**
5. Medication is being used for prophylaxis **AND;**
6. Patient has trialed at least 2 prophylactic medications from different therapeutic classes (i.e. beta blocker, antiepileptic, antidepressant, etc) for at least 2 months each.

DENIAL CRITERIA^{1,2,3}

1. Patient is not within the age range recommended by the FDA label **OR;**
2. Prescribed without consultation or is not a headache specialist, pain specialist, or neurologist **OR;**
3. Patient does not have the diagnosis of episodic or chronic migraine **OR;**
4. Patient is experiencing less than 4 migraine days per month **OR;**
5. Medication is not being used for prophylaxis **OR;**
6. Patient has not trialed at least 2 prophylactic medications from different therapeutic classes (i.e. beta blocker, antiepileptic, antidepressant, etc.) for at least 2 months each.

CAUTIONS¹

- Most common adverse reaction were injection site reactions.

DURATION OF APPROVAL

- Initial 3 months
- Reauthorization 6 months with documentation of reduction in the number of headaches per month.

ALASKA MEDICAID
Prior Authorization Criteria

QUANTITY LIMITS

- 34 days

REFERENCES / FOOTNOTES:

1. Aimovig™ [Package Insert]. Thousand Oaks, CA: Amgen Inc. May 2018. Available at: https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aimovig/aimovig_pi_hcp_english.ashx. Accessed October 15, 2018.
2. Ajovy™ [Package Insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc. Available at: <https://www.ajovy.com/globalassets/ajovy/ajovy-pi.pdf>. Accessed October 15, 2018.
3. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 April 24 ;(17):1337-45.
4. ICER Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value (July 3, 2018)